Raymond James Financial Inc. Takes Position in Hims & Hers Health, Inc. (NYSE:HIMS)

Raymond James Financial Inc. purchased a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 746,406 shares of the company's stock, valued at approximately $18,048,000. Raymond James Financial Inc. owned 0.34% of Hims & Hers Health as of its most recent SEC filing.

Several other large investors have also made changes to their positions in HIMS. HighTower Advisors LLC bought a new stake in Hims & Hers Health during the 3rd quarter valued at approximately $207,000. MML Investors Services LLC purchased a new stake in Hims & Hers Health during the 3rd quarter valued at approximately $197,000. Barclays PLC raised its position in shares of Hims & Hers Health by 9.7% during the third quarter. Barclays PLC now owns 308,363 shares of the company's stock valued at $5,680,000 after buying an additional 27,231 shares during the last quarter. Sanctuary Advisors LLC lifted its holdings in shares of Hims & Hers Health by 26.8% in the third quarter. Sanctuary Advisors LLC now owns 26,057 shares of the company's stock worth $480,000 after buying an additional 5,505 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of Hims & Hers Health by 102.0% in the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company's stock worth $5,349,000 after buying an additional 146,621 shares in the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 2,203 shares of the company's stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $28.78, for a total value of $63,402.34. Following the transaction, the insider now directly owns 8,007 shares in the company, valued at $230,441.46. This represents a 21.58 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Andrew Dudum sold 100,000 shares of Hims & Hers Health stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $35.22, for a total transaction of $3,522,000.00. Following the sale, the chief executive officer now directly owns 27,918 shares of the company's stock, valued at $983,271.96. This represents a 78.18 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 730,302 shares of company stock worth $28,528,874. 17.71% of the stock is currently owned by company insiders.

Hims & Hers Health Stock Performance

NYSE HIMS traded up $1.44 on Thursday, hitting $28.15. 11,904,007 shares of the stock were exchanged, compared to its average volume of 22,359,766. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98. The firm has a market capitalization of $6.25 billion, a P/E ratio of 63.97 and a beta of 1.65. The stock has a fifty day moving average price of $35.50 and a two-hundred day moving average price of $30.78.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company had revenue of $481.14 million for the quarter, compared to the consensus estimate of $494.56 million. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on HIMS. Piper Sandler lifted their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a "neutral" rating in a report on Tuesday, February 25th. Truist Financial decreased their target price on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating on the stock in a research report on Thursday, April 10th. Needham & Company LLC increased their price target on Hims & Hers Health from $31.00 to $61.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Morgan Stanley downgraded Hims & Hers Health from an "overweight" rating to an "equal weight" rating and lifted their price objective for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Finally, Citigroup reiterated a "sell" rating on shares of Hims & Hers Health in a research report on Wednesday, April 2nd. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $38.25.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.